Latham & Watkins Advises on Orchestra BioMed’s US$75 Million Public Offering

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (the Company), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, has announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of US$5 per share (the Offering). In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities are being offered by the Company. The Offering is expected to close on November 9, 2026, subject to customary closing conditions.

Latham & Watkins LLP advised the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili, with associates Kathleen Mehary, Yulong Li, and Renyang Gao.